Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Injury, poisoning and procedural complications

  • 286 clinical trials
  • 125 recruiting
  • 217 conditions
  • 25 countries

Conditions in this area

217 conditions with trials, the busiest first

Procedural pain29Subarachnoid haemorrhage16Chronic graft versus host disease13Craniocerebral injury10Graft versus host disease10Kidney transplant rejection10Short-bowel syndrome10Acute graft versus host disease9Hypoparathyroidism9Medical device site joint infection8Thermal burn8Post procedural complication7Hip fracture6Cardiac function disturbance postoperative5Retinopathy of prematurity5Transplant rejection5Complex regional pain syndrome4Postoperative analgesia4Radius fracture4Skin wound4Spinal cord injury4Acute graft versus host disease in intestine3Acute graft versus host disease in skin3Acute kidney injury3+193

Clinical trials in Injury, poisoning and procedural complications

286 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

286 clinical trials

Craniocerebral injury

Recruiting

Phase 2a Study of Safety, Tolerability and Efficacy of Intranasal Cenegermin in Adults with Moderate to Severe Subacute Traumatic Brain Injury

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Osteoporotic fracture

Recruiting

Preventing Neuropathic Pain After Osteoporotic Vertebral Fracture with a 5% Lidocaine Patch in Adults

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lidocaine
  • Sponsor:University Hospital Of Clermont-Ferrand

Persistent corneal epithelial defect

Recruiting

Cenegermin Eye Drops for Persistent Corneal Epithelial Defect in Patients with Persistent Corneal Epithelial Defect

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Kidney transplant rejection

Recruiting

Frexalimab versus Tacrolimus for Prevention of Kidney Transplant Rejection in Adult Kidney Transplant Recipients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Endometrial cancer+12

Recruiting

A study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors.

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Pouchitis

Recruiting

Study of guselkumab and dietary changes for patients with recurring or difficult-to-treat pouchitis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:UZ Leuven

Pain+3

Recruiting

A study to evaluate the safety and how the body processes the combination of ibuprofen and paracetamol in children and adolescents with acute pain

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Ibuprofen
  • Sponsor:Aft Pharmaceuticals Limited

Kidney transplant rejection

Recruiting

A study of allogeneic adipose-derived mesenchymal stem cells for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:ALLOGENEIC ADIPOSE-DERIVED MESENCHYMAL STEM CELLS IN VITRO EXPANDED
  • Sponsor:Region Midtjylland

Cardiac function disturbance postoperative+1

Recruiting

A study to evaluate the effectiveness of R2R01 in preventing acute kidney injury in patients at high risk following heart surgery.

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:R2R01
  • Sponsor:River 2 Renal Corp.

Skin wound

Recruiting

Study of the effect of hyperbaric oxygen therapy on the bacteria in chronic wounds

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen
  • Sponsor:Medical University Of Graz

Short-bowel syndrome

Recruiting

Study of glepaglutide compared to placebo for patients with short bowel syndrome with intestinal failure

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Glepaglutide
  • Sponsor:Zealand Pharma A/S

Anaesthetic complication neurological

Recruiting

Study of flumazenil for preventing emergence delirium in children after ear, nose and throat surgery

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Sodium Chloride
  • Sponsor:Rheinische Friedrich-Wilhelms-Universitaet Bonn

Substances studied in this area

The therapies tested most often in Injury, poisoning and procedural complications trials.

Sodium Chloride44 clinical trialsParacetamol15 clinical trialsLidocaine Hydrochloride11 clinical trialsMycophenolate Mofetil8 clinical trialsOxygen7 clinical trialsRopivacaine Hydrochloride7 clinical trialsTacrolimus7 clinical trialsAmoxicillin6 clinical trialsPrednisone6 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.